title: A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma.
abstract: Nutritional support may play an important role in management of liver cirrhosis (LC) associated with unresectable hepatocellular carcinoma (HCC). Total protein and albumin deteriorate in patients with LC undergoing trans-arterial chemoembolization (TACE). Therefore, in this study, we examined the hypothesis that short-term administration of branched-chain amino acids (BCAA) will prevent a fall in total protein and albumin in the perioperative period. The subjects were 56 patients who underwent TACE for HCC between 2004 and 2005 at Nagasaki University Hospital. The patients were randomly placed in the BCAA group (n = 28) or a control group (n = 28). The patients in the BCAA group consumed a snack containing 50 g of BCAA once a day at 10:00 pm starting 1 day before TACE and continuing until 2 weeks after TACE. A comparison of baseline and end point data showed greater decreases in the concentrations of total protein, albumin, cholinesterase, and total cholesterol and in the red blood cell count in the control group compared to the BCAA group. Ammonia levels decreased in the BCAA group and increased in the control group. Our findings indicate that a BCAA supplement taken orally as a late evening snack prevents suppression of liver function by TACE in patients with LC complicated with HCC during the 2-week period after TACE.
authors.affiliation: The First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan. shige-ygc@umin.ac.jp
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Takeshita
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Ichikawa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakao
authors.forename: Hisamitsu
authors.initials: H
authors.lastname: Miyaaki
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Shibata
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Matsuzaki
authors.forename: Toru
authors.initials: T
authors.lastname: Muraoka
authors.forename: Takuya
authors.initials: T
authors.lastname: Honda
authors.forename: Masashi
authors.initials: M
authors.lastname: Otani
authors.forename: Motohisa
authors.initials: M
authors.lastname: Akiyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Miuma
authors.forename: Esuke
authors.initials: E
authors.lastname: Ozawa
authors.forename: Masumi
authors.initials: M
authors.lastname: Fujimito
authors.forename: Katsumi
authors.initials: K
authors.lastname: Eguchi
mesh_terms: D000368:Aged; D000597:Amino Acids, Branched-Chain / Q000008:administration & dosage / Q000627:therapeutic use*; D000641:Ammonia / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D002784:Cholesterol / Q000097:blood; D002802:Cholinesterases / Q000097:blood; D019587:Dietary Supplements; D004906:Erythrocyte Count; D005260:Female; D005527:Food, Fortified; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000178:diet therapy* / Q000209:etiology; D008113:Liver Neoplasms / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012709:Serum Albumin
chemical_list: D000597:Amino Acids, Branched-Chain; D001798:Blood Proteins; D012709:Serum Albumin; D000641:Ammonia; D002784:Cholesterol; D002802:Cholinesterases